Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER Director Woodcock notes breakthrough program often pushes sponsors to modernize production processes.


Related Content

Breakthrough In Two Pages: FDA Offers Preliminary Advice
PDUFA Negotiations: Early Communications, Breakthrough Still On Docket
Breakthrough Requests: FDA Adds Quick Screen To Pare Workload
Breakthrough Designation Is A Two-Way Street, FDA Cautions Sponsors
CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
Industry Wants A Breakthrough Therapy, Even Without All The Standards
GMP Carrots For Quality: FDA Considers Incentives To Adopt Quality Systems


Related Companies